FDA allows generic version of scarce cancer drug
WASHINGTON (
AP) — Federal regulators say approval of the first generic version of cancer drug Doxil will help resolve a lingering shortage triggered by manufacturing deficiencies.
The shortage of the Johnson & Johnson injectable medication, made under contract by Ben Venue Laboratories, has continued on and off for a few years. It's resulted in rationing, with some patients with ovarian and other cancers getting less-effective care, and disrupted studies testing Doxil against possible new treatments.
The Food and Drug Administration says it's approved a generic version, called doxorubicin, made by Sun Pharma Global FZE. Last February, the FDA authorized temporary importation from India of a brand-name version, called Lipodox, also made by Sun Pharma. It's a subsidiary of an Indian drugmaker.
Meanwhile, J&J continues to seek a contract manufacturer to replace Ben Venue.
Tags:
ap, food and drug administration, fda, ben venue, patients, sun pharma, health, breast cancer, drug administration, india, generic version, chemotherapy, cancer, washington, shortage, pharmacology, studies, subsidiary, approval, federal regulators, deficiencies, pharmaceutical drug, brand-name version, cancers, cancer drug, cancer drug doxil, pharma global fze, scarce cancer drug, ben venue laboratories, johnson injectable medication, possible new treatments, temporary importation, less-effective care, indian drugmaker, contract manufacturer, rationing, doxorubicin
Print Page
